Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Short-course radiotherapy followed by chemotherapy and total mesorectal excision improved outcomes for patients with high-risk locally advanced rectal cancer.
Patients with nonmuscle-invasive bladder cancer who received intravesical chemotherapy after transurethral resection of bladder tumor had a significantly lower 30-day complication rate compared with those who did not receive intravesical chemotherapy.
Women were approximately 1.7 and 3.0 times more likely than men to experience recurrence and progression, respectively, following BCG treatment for nonmuscle-invasive bladder cancer.
Trial data are still needed to clearly define the risks and benefits of using radiation therapy for nonmuscle-invasive bladder cancer, according to investigators.
In a subgroup analysis, neither patient characteristics nor prior treatment history influenced response to a novel intravesical gene therapy for BCG-unresponsive bladder cancer.
Patients who received BCG induction within 3 weeks or 3 weeks or more after surgery for nonmuscle-invasive bladder cancer did not differ in their rates of BCG intolerance and recurrence- and progression-free survival, a study found.
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Compared with patients who undergo surgery alone for abdominal or pelvic cancers, those who receive radiation and chemotherapy are at elevated risk for secondary sarcomas.
As current guidelines only include a weak recommendation to offer perioperative chemotherapy to patients with muscle-invasive upper tract urothelial carcinoma, a new meta-analysis including evidence up to February 2020 provides potentially useful information.
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
The 2020 update highlights the importance of accurate diagnosis of upper tract urothelial carcinoma, risk stratification, close follow-up of patients receiving kidney-sparing management, and other key aspects of care.
